Floatz logo

ATORVASTATIN

Inherited Lipid Metabolism Disorder

Johns Hopkins UniversitySmall moleculePhase 4 / ApprovedActive
A
83/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
75/ 100
Competitive Position
95/ 100

Competitive context

17 Active assets in the Inherited Lipid Metabolism Disorder cohort.

Asset / SponsorPhaseRating
Rosuvastatin
Korea University Anam Hospital
Phase 4A
Metformin
RenJi Hospital
Phase 4BBB
Ezetimibe
Samsung Medical Center
Phase 4BBB
SIMVASTATIN
Eli Lilly and Company
Phase 4BBB
Fenofibrate
Lewai Sharki Abdulaziz, MSc PhD
Phase 4BBB

View all 50 →

Same molecule, other indications

ATORVASTATIN is also rated in:

hyperlipidemiaDormant
BBB
Indicative · Phase 4
79 / 100
View asset →
cardiovascular disorderActive
BBB
Indicative · Phase 4
76 / 100
View asset →
abdominal obesity-metabolic syndromeDormant
BBB
Indicative · Phase 4
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →